ESM 1 (download DOCX (DOCX 319 KB) Rights and permissions Open Access This article is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License, which permits any non-commercial use, sharing, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if you modified the licensed material
This effect became statistically significant from the tenth day of the study onward, as patients were titrated to increasingly higher doses of liraglutide
- Semaglutide led to a significant reduction in HbA1c levels compared to placebo- Patients receiving semaglutide experienced significant weight loss compared to those on placebo PIONEER Trials (Peptide Innovation for Early Diabetes Treatment): The PIONEER (Peptide Innovation for Early Diabetes Treatment) trials were a series of global, randomized, controlled clinical trials that investigated the efficacy, safety, and tolerability of oral semaglutide, a GLP-1 receptor agonist, in patients with type 2 diabetes
One of the biggest concerns for employers who are considering coverage may be the large potential market due to prevalence of obesity
